With the new Congress and Administration in place, ASCO has been on Capitol Hill monitoring the issues that affect the cancer care community, and educating lawmakers on how best to serve Americans with cancer. In particular, ASCO is closely tracking efforts to repeal and replace the Affordable Care Act (ACA), the discussion on the future of Medicaid, and relevant cabinet appointments.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO’s "Criteria for High-Quality Clinical Pathways in Oncology," is now featured as a special article in the Journal of Oncology Practice. ASCO developed the 15 inter-related criteria to provide an overarching framework for assessing pathway programs in the United States and to guide stakeholders in assessing the quality, utility and integrity of clinical pathways in oncology.
On February 14, SAP’s online course “The Future of Genomics and Precision Medicine” will begin, and enrollment for the free course is now open.
In a congressional briefing on Capitol Hill, ASCO presented Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer, announced immunotherapy 2.0 as the advance of the year, and urged Congress to support increased federal funding for research.
On February 2, 2017, the U.S. Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Company) for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy.
A new study in the Journal of Managed Care & Specialty Pharmacy found that gaps in the quality measures used to assess cancer care may obscure problems in care delivery and lead to missed opportunities to improve patient outcomes.
An American Medical Association (AMA)-led coalition including ASCO and 15 other health care organizations today urged health plans, benefit managers, and other stakeholders to reform utilization management policies, including prior authorization requirements, imposed on medical tests, procedures, devices, and drugs.
On January 24, 2017, the Journal of the American Medical Association (JAMA), published “Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014” by Modak et al. The study found that cancer deaths in the U.S. declined by 20 percent from 1980-2014, but there were large differences in cancer mortality as well as areas with unusually higher mortality rates across counties. The following is a statement from Daniel F. Hayes, MD, FACP, FASCO, President of the American Society of Clinical Oncology (ASCO).
ASCO is hosting a congressional briefing to announce Clinical Cancer Advances 2017: ASCO’s Annual Report on Progress Against Cancer and outline how Congress can shape the future of cancer care.
A new set of articles in the Journal of Oncology Practice seek to gain physicians and patients’ perspectives regarding the ethical implementation of a rapid learning system (RLS) in oncology care.
ASCO has submitted comments to the National Institutes of Health (NIH) in response to a Request for Information (RFI) on data sharing and management (NOT-OD-17-015).
As the new Administration gets underway and Congress considers proposals to repeal and replace the Affordable Care Act, ASCO is closely monitoring developments and will continue to strongly urge policymakers to provide access to affordable and sufficient healthcare coverage for all Americans, as stated in the society’s principles for patient-centered healthcare reform.
ASCO is hosting two upcoming events for oncology practices discuss quality and business challenges, including MACRA, alternative payment models, EHRs, and physician burnout.
On January 18, 2017, the Department of Health and Human Services (HHS), along with more than a dozen other federal agencies, finalized updates to the Common Rule, which protects human subjects in biomedical research. This is the first time the Common Rule has been updated in nearly three decades, and the changes make major strides in modernizing protections for human subjects.
We commend the Food and Drug Administration (FDA) for establishing the Oncology Center of Excellence (OCE) with Dr. Richard Pazdur as its director. The FDA has provided not only regulatory guidance but also intellectual leadership in the development of oncology products and this new OCE will build on that past, creating a larger community of scientists and clinician experts within the agency. ASCO looks forward to working with the OCE and the new administration to help improve the lives of people living with cancer.